Company profile: Caraway Therapeutics
1.1 - Company Overview
Company description
- Provider of precision small-molecule therapeutics for CNS and rare diseases, developing medicines that enhance cellular clearance by activating the lysosome to remove toxic materials and defective cellular components. Leverages modulation of mitophagy and autophagy to use natural clearance pathways, preventing cell damage and treating neurodegenerative disease.
Products and services
- Precision Medicines for CNS and Rare Diseases: Small-molecule therapeutics that activate the lysosome to enhance cellular clearance, eliminating toxic materials and defective components in CNS and rare disease indications
- Mitophagy and Autophagy Modulation: Pathway-specific therapeutics that tune cellular clearance to degrade damaged organelles and aggregated proteins, addressing neurodegenerative disease via targeted modulation of mitophagy and autophagy
- Targeted Approach: Mechanism-driven treatments that harness innate cellular clearance pathways to accelerate removal of toxic materials and prevent cell damage, leveraging the body’s natural degradation machinery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Caraway Therapeutics
BlackThorn Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage neurobehavioral health, pioneering the next generation of artificial intelligence.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlackThorn Therapeutics company profile →
Basking Biosciences
HQ: United States
Website
- Description: Provider of commercialization of technology developed at Duke and Ohio State Universities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Basking Biosciences company profile →
Semnur Pharma
HQ: United States
Website
- Description: Provider of specialty pharmaceutical development focused on the clinical and commercial advancement of innovative products for pain management, including SP-102 (SEMDEXA), a non-opioid injectable corticosteroid gel designed to treat moderate to severe chronic radicular pain/sciatica via epidural injection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semnur Pharma company profile →
MindMed
HQ: United States
Website
- Description: Provider of psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses, building a drug development pipeline based on psilocybin, LSD, MDMA, DMT, and 18-MC. Offerings include MM120 (LSD D-tartrate) for psychiatry, pain, and substance use disorders; MM402 (R(-)-MDMA) for social functioning in ASD; digital medicine using AI models; clinical trials; and an expanded access policy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MindMed company profile →
Gabather
HQ: Sweden
Website
- Description: Provider of research and development of innovative therapeutics for neuropsychiatric disorders, focusing on pro-cognitive drug candidates targeting GABAA receptor systems for central nervous system disorders, including GT-002, a small-molecule GABAA receptor PAM in clinical development to improve learning and memory, reduce anxiety, and promote social interaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gabather company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Caraway Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Caraway Therapeutics
2.2 - Growth funds investing in similar companies to Caraway Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Caraway Therapeutics
4.2 - Public trading comparable groups for Caraway Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →